REG - Craneware plc - Purchase of Shares by Director and TVR

CranewareAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250428:nRSb3935Ga&default-theme=true

RNS Number : 3935G  Craneware plc  28 April 2025

 

Craneware plc

 

("Craneware" or the "Company" or the "Group")

 

Purchase of Shares by Director and Total Voting Rights

 

 

28 April 2025 - Craneware (AIM: CRW.L), the market leader in Value Cycle
software solutions for the US healthcare market, announces that on 24 April
2025, Will Whitehorn, Chair of the Company, purchased 1,911 Ordinary Shares of
1p each in the capital of the Company at a price of 1,584 pence per Ordinary
Share.

 

Following the purchase of Ordinary Shares, Mr. Whitehorn holds 6,500 Ordinary
Shares in the capital of the Company, representing 0.018% of the Company's
issued share capital (excluding Ordinary Shares held in treasury).

 

Total Voting Rights

In the period since 1 April 2025 the Company has transferred a total of 1,118
Ordinary Shares previously held in treasury to satisfy the exercise of share
options by employees. As a result, the Company's issued share capital now
consists of 35,542,169 Ordinary Shares, of which 132,367 remain held in
treasury. Accordingly, the total number of Ordinary Shares in the Company with
voting rights is 35,409,802.This figure may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them:

 

1.   Details of the Restricted Person / person closely associated with him
or her

a)
Name
        William Whitehorn

 

2.   Reason for the notification

 a) Position / status                 Chair
 b) Initial notification / Amendment  Initial notification

 

3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

 a) Name  Craneware plc
 b) LEI   213800O2CTJ1YFXNXG05

 

4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted

 

 a) Description of the financial instrument, type of instrument  Ordinary shares of 1p each in the capital of Craneware plc
 b) Identification code                                          ISIN GB00B2425G68
 c) Nature of the transaction                                    Purchase of Ordinary Shares
 d) Price(s) and volume(s)                                       Volume(s) 1,911, Price(s) £15.84
 e) Aggregated information:                                      N/A (single transaction)

i. Aggregated volume            -

ii. Price(s)                              -

 f) Date of the transaction                                              2025-04-24
 g) Place of the transaction                                             London Stock Exchange (XLON)

 

 

 

For further information, please contact:

 

 Craneware plc                                    +44 (0)131 550 3100
 Keith Neilson, CEO
 Craig Preston, CFO

 Alma Strategic Communications (Financial PR)     +44 (0)20 3405 0205
 Caroline Forde, Kinvara Verdon, Sarah Peters     craneware@almastrategic.com

 Peel Hunt (NOMAD and Joint Broker)               +44 (0)20 7418 8900
 Neil Patel, Benjamin Cryer, Kate Bannatyne

 Investec Bank PLC (Joint Broker)                 +44 (0)20 7597 5970
 Patrick Robb, Virginia Bull, James Smith
 ( )                                              ( )
 Berenberg (Joint Broker)                         +44 (0)20 3207 7800
 Mark Whitmore, Richard Andrews, Dan Gee-Summons

 

About Craneware

 

The Craneware Group (AIM:CRW.L), is the market leader in value cycle
solutions. For 25 years, we have collaborated with U.S. healthcare providers
to optimize revenue integrity, pricing intelligence, decision support, labor
productivity, business of pharmacy, and 340B program management. 

 

Customers choose Trisus®, a HITRUST- and SOC2 Type II-certified, SaaS
platform, to achieve operational and financial excellence in pursuit of their
healthcare mission - delivering quality care to their communities. The
Craneware Group - Transforming the Business of Healthcare.

 

Learn more at www.thecranewaregroup.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUBVKRVKUSUAR